Tags

Type your tag names separated by a space and hit enter

Indomethacin for post-ERCP pancreatitis prophylaxis: another attempt at the Holy Grail.
Am J Gastroenterol. 2007 May; 102(5):984-6.AJ

Abstract

Acute pancreatitis continues to be the most dreaded complication after ERCP. Various risk factors for post-ERCP pancreatitis have now been recognized including patient-related, procedure-related, and operator-related factors. Numerous attempts at finding the ideal pharmacological agent for prevention of this complication have been made but nearly all drugs evaluated have failed to demonstrate clinical efficacy. Predictably, these agents have shown promise in early single-center studies but met with disappointing results when tested in larger multicenter randomized controlled trials. As the quest for the "magic bullet" continues, selecting patients with appropriate indications for ERCP and prophylactic pancreatic duct stenting in high-risk cases appears to be the best approach to averting this complication.

Authors

No affiliation info availableNo affiliation info available

Pub Type(s)

Comment
Editorial

Language

eng

PubMed ID

17489783

Citation

Wagh, Mihir S., and Stuart Sherman. "Indomethacin for post-ERCP Pancreatitis Prophylaxis: Another Attempt at the Holy Grail." The American Journal of Gastroenterology, vol. 102, no. 5, 2007, pp. 984-6.
Wagh MS, Sherman S. Indomethacin for post-ERCP pancreatitis prophylaxis: another attempt at the Holy Grail. Am J Gastroenterol. 2007;102(5):984-6.
Wagh, M. S., & Sherman, S. (2007). Indomethacin for post-ERCP pancreatitis prophylaxis: another attempt at the Holy Grail. The American Journal of Gastroenterology, 102(5), 984-6.
Wagh MS, Sherman S. Indomethacin for post-ERCP Pancreatitis Prophylaxis: Another Attempt at the Holy Grail. Am J Gastroenterol. 2007;102(5):984-6. PubMed PMID: 17489783.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Indomethacin for post-ERCP pancreatitis prophylaxis: another attempt at the Holy Grail. AU - Wagh,Mihir S, AU - Sherman,Stuart, PY - 2007/5/11/pubmed PY - 2007/6/29/medline PY - 2007/5/11/entrez SP - 984 EP - 6 JF - The American journal of gastroenterology JO - Am J Gastroenterol VL - 102 IS - 5 N2 - Acute pancreatitis continues to be the most dreaded complication after ERCP. Various risk factors for post-ERCP pancreatitis have now been recognized including patient-related, procedure-related, and operator-related factors. Numerous attempts at finding the ideal pharmacological agent for prevention of this complication have been made but nearly all drugs evaluated have failed to demonstrate clinical efficacy. Predictably, these agents have shown promise in early single-center studies but met with disappointing results when tested in larger multicenter randomized controlled trials. As the quest for the "magic bullet" continues, selecting patients with appropriate indications for ERCP and prophylactic pancreatic duct stenting in high-risk cases appears to be the best approach to averting this complication. SN - 0002-9270 UR - https://www.unboundmedicine.com/medline/citation/17489783/Indomethacin_for_post_ERCP_pancreatitis_prophylaxis:_another_attempt_at_the_Holy_Grail_ L2 - https://Insights.ovid.com/pubmed?pmid=17489783 DB - PRIME DP - Unbound Medicine ER -